Multicell Techs Stock Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Multicell Techs are completely uncorrelated.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Multicell Techs are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile technical and fundamental indicators, Multicell Techs unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Multicell |
Multicell Techs Relative Risk vs. Return Landscape
If you would invest 0.00 in Multicell Techs on October 31, 2025 and sell it today you would earn a total of 0.00 from holding Multicell Techs or generate 0.0% return on investment over 90 days. Multicell Techs is currently generating 15.0% in daily expected returns and assumes 129.9609% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Multicell, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Multicell Techs Target Price Odds to finish over Current Price
The tendency of Multicell Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.00 | 90 days | 0.00 | about 55.13 |
Based on a normal probability distribution, the odds of Multicell Techs to move above the current price in 90 days from now is about 55.13 (This Multicell Techs probability density function shows the probability of Multicell Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Multicell Techs has the beta coefficient that is very close to zero. This indicates the returns on DOW JONES INDUSTRIAL and Multicell Techs do not appear to be related. Additionally It does not look like Multicell Techs' alpha can have any bearing on the current valuation. Multicell Techs Price Density |
| Price |
Predictive Modules for Multicell Techs
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Multicell Techs. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Multicell Techs' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Multicell Techs Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Multicell Techs is not an exception. The market had few large corrections towards the Multicell Techs' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Multicell Techs, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Multicell Techs within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.000062 | |
Ir | Information ratio | 0.00 |
Multicell Techs Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Multicell Techs for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Multicell Techs can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Multicell Techs is way too risky over 90 days horizon | |
| Multicell Techs has some characteristics of a very speculative penny stock | |
| Multicell Techs appears to be risky and price may revert if volatility continues | |
| Multicell Techs currently holds 36.43 K in liabilities. Multicell Techs has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Multicell Techs until it has trouble settling it off, either with new capital or with free cash flow. So, Multicell Techs' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Multicell Techs sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Multicell to invest in growth at high rates of return. When we think about Multicell Techs' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 49.32 K. Net Loss for the year was (380.07 K) with profit before overhead, payroll, taxes, and interest of 49.32 K. | |
| Multicell Techs currently holds about 281.12 K in cash with (1.09 M) of positive cash flow from operations. |
Multicell Techs Fundamentals Growth
Multicell Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Multicell Techs, and Multicell Techs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Multicell Pink Sheet performance.
| Return On Asset | -1.36 | |||
| Profit Margin | (0.31) % | |||
| Operating Margin | (0.60) % | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 5 B | |||
| Price To Sales | 0.01 X | |||
| Revenue | 49.32 K | |||
| Cash And Equivalents | 281.12 K | |||
| Total Debt | 36.43 K | |||
| Cash Flow From Operations | (1.09 M) | |||
| Total Asset | 126.22 K | |||
| Retained Earnings | (50.74 M) | |||
| Current Asset | 295 K | |||
| Current Liabilities | 1.54 M | |||
About Multicell Techs Performance
Assessing Multicell Techs' fundamental ratios provides investors with valuable insights into Multicell Techs' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Multicell Techs is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island. Multicell Techs operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about Multicell Techs performance evaluation
Checking the ongoing alerts about Multicell Techs for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Multicell Techs help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Multicell Techs is way too risky over 90 days horizon | |
| Multicell Techs has some characteristics of a very speculative penny stock | |
| Multicell Techs appears to be risky and price may revert if volatility continues | |
| Multicell Techs currently holds 36.43 K in liabilities. Multicell Techs has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Multicell Techs until it has trouble settling it off, either with new capital or with free cash flow. So, Multicell Techs' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Multicell Techs sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Multicell to invest in growth at high rates of return. When we think about Multicell Techs' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 49.32 K. Net Loss for the year was (380.07 K) with profit before overhead, payroll, taxes, and interest of 49.32 K. | |
| Multicell Techs currently holds about 281.12 K in cash with (1.09 M) of positive cash flow from operations. |
- Analyzing Multicell Techs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Multicell Techs' stock is overvalued or undervalued compared to its peers.
- Examining Multicell Techs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Multicell Techs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Multicell Techs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Multicell Techs' pink sheet. These opinions can provide insight into Multicell Techs' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Multicell Pink Sheet Analysis
When running Multicell Techs' price analysis, check to measure Multicell Techs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Multicell Techs is operating at the current time. Most of Multicell Techs' value examination focuses on studying past and present price action to predict the probability of Multicell Techs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Multicell Techs' price. Additionally, you may evaluate how the addition of Multicell Techs to your portfolios can decrease your overall portfolio volatility.